NO20090266L - Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer - Google Patents

Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer

Info

Publication number: NO20090266L
Authority: NO; Norway
Prior art keywords: treatment; mediated diseases; derivatives useful; gpr38 receptor; piperazinyl derivatives
Prior art date: 2006-06-28

Application number

NO20090266A

Other languages

English (en)

Norwegian (no)

Inventor

Mervyn Thompson

Susan Marie Westaway

Darren Jason Mitchell

Jonathan Thomas Seal

Samantha Louisa Brown

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-28

Filing date

2009-01-16

Publication date

2009-03-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090266(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-06-28 Priority claimed from GB0612844A external-priority patent/GB0612844D0/en

2007-06-14 Priority claimed from GB0711525A external-priority patent/GB0711525D0/en

2009-01-16 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2009-03-17 Publication of NO20090266L publication Critical patent/NO20090266L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

NO20090266A 2006-06-28 2009-01-16 Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer NO20090266L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0612844A GB0612844D0 (en)	2006-06-28	2006-06-28	Compounds
GB0711525A GB0711525D0 (en)	2007-06-14	2007-06-14	Compounds
PCT/EP2007/056342 WO2008000729A1 (en)	2006-06-28	2007-06-26	Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases

Publications (1)

Publication Number	Publication Date
NO20090266L true NO20090266L (no)	2009-03-17

Family

ID=38476358

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20090266A NO20090266L (no)	2006-06-28	2009-01-16	Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer

Country Status (29)

Country	Link
US (2)	US7700599B2 (da)
EP (1)	EP2041093B1 (da)
JP (1)	JP5028484B2 (da)
KR (1)	KR20090031688A (da)
AR (1)	AR061656A1 (da)
AT (1)	ATE465150T1 (da)
AU (1)	AU2007263712B2 (da)
BR (1)	BRPI0713443A2 (da)
CA (1)	CA2655540A1 (da)
CR (1)	CR10497A (da)
CY (1)	CY1110190T1 (da)
DE (1)	DE602007006019D1 (da)
DK (1)	DK2041093T3 (da)
EA (1)	EA015820B1 (da)
ES (1)	ES2344484T3 (da)
HR (1)	HRP20100284T1 (da)
IL (1)	IL195900A0 (da)
JO (1)	JO2645B1 (da)
MA (1)	MA30539B1 (da)
MX (1)	MX2009000110A (da)
MY (1)	MY147677A (da)
NO (1)	NO20090266L (da)
NZ (1)	NZ573450A (da)
PE (1)	PE20080345A1 (da)
PL (1)	PL2041093T3 (da)
PT (1)	PT2041093E (da)
SI (1)	SI2041093T1 (da)
TW (1)	TWI391386B (da)
WO (1)	WO2008000729A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0611907D0 (en) *	2006-06-15	2006-07-26	Glaxo Group Ltd	Compounds
MY150098A (en) *	2005-07-26	2013-11-29	Glaxo Group Ltd	Benzylpiperazine derivates and their medical use
GB0524814D0 (en)	2005-12-05	2006-01-11	Glaxo Group Ltd	Compounds
SI2041093T1 (sl) *	2006-06-28	2010-07-30	Glaxo Group Ltd	Derivati piperazinila, uporabni pri zdravljenju bolezni, ki jih posreduje receptor gpr38
GB0723317D0 (en) *	2007-11-28	2008-01-09	Glaxo Group Ltd	Compounds
US8697877B2 (en)	2009-02-27	2014-04-15	Raqualia Pharma Inc.	Oxyindole derivatives with motilin receptor agonistic activity
US9452980B2 (en) *	2009-12-22	2016-09-27	Hoffmann-La Roche Inc.	Substituted benzamides
WO2011092293A2 (en)	2010-02-01	2011-08-04	Novartis Ag	Cyclohexyl amide derivatives as crf receptor antagonists
CN102762572A (zh)	2010-02-01	2012-10-31	诺瓦提斯公司	作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
CN102753527B (zh)	2010-02-02	2014-12-24	诺华股份有限公司	用作crf受体拮抗剂的环己基酰胺衍生物
PT2623492E (pt)	2010-09-27	2014-08-29	Daiichi Sankyo Co Ltd	Composto derivado de ciclo-hexano
US9321727B2 (en) *	2011-06-10	2016-04-26	Hoffmann-La Roche Inc.	Pyridine derivatives as agonists of the CB2 receptor
EP3757102A1 (en)	2016-03-17	2020-12-30	F. Hoffmann-La Roche AG	5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
TWI794994B (zh) *	2020-09-25	2023-03-01	大陸商上海美悅生物科技發展有限公司	嘧啶甲醯胺類化合物及其應用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5385912A (en) *	1991-03-08	1995-01-31	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
TW355711B (en)	1992-11-04	1999-04-11	Chugai Pharmaceutical Co Ltd	Erythromycin derivatives
JPH06211886A (ja)	1992-11-04	1994-08-02	Chugai Pharmaceut Co Ltd	エリスロマイシン誘導体
US5593994A (en) *	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
JP3901239B2 (ja)	1996-03-13	2007-04-04	大正製薬株式会社	アリールアルカン誘導体
US5965578A (en) *	1996-04-03	1999-10-12	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
DE19644195A1 (de)	1996-10-24	1998-04-30	Solvay Pharm Gmbh	10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU4968997A (en) *	1996-11-26	1998-06-22	Chugai Seiyaku Kabushiki Kaisha	13-membered ring macrolide compounds, medicine containing the same, and process for producing the same
US6060491A (en) *	1997-06-19	2000-05-09	Dupont Pharmaceuticals	6-membered aromatics as factor Xa inhibitors
US5972939A (en) *	1997-10-28	1999-10-26	Ortho-Mcneil Pharmaceutical, Inc.	Cyclopentene derivatives useful as antagonists of the motilin receptor
DE19805822B4 (de)	1998-02-13	2009-02-05	Solvay Pharmaceuticals Gmbh	11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6165985A (en)	1998-02-13	2000-12-26	Solvay Pharmaceuticals Gmbh	11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
GB9804734D0 (en) *	1998-03-05	1998-04-29	Pfizer Ltd	Compounds
PL215901B1 (pl) *	1999-04-15	2014-02-28	Bristol Myers Squibb Co	Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US20020052380A1 (en) *	2000-02-18	2002-05-02	Dinsmore Christopher J.	Inhibitors of prenyl-protein transferase
US20020010184A1 (en) *	2000-02-18	2002-01-24	Dinsmore Christopher J.	Inhibitors of prenyl-protein transferase
AU2001249144A1 (en) *	2000-03-13	2001-09-24	Ortho-Mcneil Pharmaceutical, Inc.	Novel cyclopentene derivatives useful as antagonists of the motilin receptor
US6423714B2 (en) *	2000-03-13	2002-07-23	Ortho Mcneil-Pharmaceutical, Inc..	Cyclohexene derivatives useful as antagonists of the motilin receptor
US6384031B2 (en) *	2000-03-13	2002-05-07	Ortho-Mcneil Pharmaceutical, Inc.	Cyclobutene derivatives useful as antagonists of the motilin receptor
US6511980B2 (en) *	2000-05-05	2003-01-28	Ortho Mcneil Pharmaceutical, Inc.	Substituted diamine derivatives useful as motilin antagonists
GB0013378D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Use of therapeutic benzamide derivatives
US7105682B2 (en) *	2001-01-12	2006-09-12	Amgen Inc.	Substituted amine derivatives and methods of use
US7102009B2 (en) *	2001-01-12	2006-09-05	Amgen Inc.	Substituted amine derivatives and methods of use
US6878714B2 (en) *	2001-01-12	2005-04-12	Amgen Inc.	Substituted alkylamine derivatives and methods of use
EP1392679B1 (de)	2001-05-10	2005-11-02	Solvay Pharmaceuticals GmbH	Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6977264B2 (en) *	2001-07-25	2005-12-20	Amgen Inc.	Substituted piperidines and methods of use
GB0129013D0 (en) *	2001-12-04	2002-01-23	Glaxo Group Ltd	Compounds
GB0129015D0 (en) *	2001-12-04	2002-01-23	Glaxo Group Ltd	Compounds
SE0203302D0 (sv) *	2002-11-07	2002-11-07	Astrazeneca Ab	Novel Compounds
US7223788B2 (en) *	2003-02-14	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US7338954B2 (en)	2003-09-17	2008-03-04	Bristol-Myers Squibb Company	Compounds useful as motilin agonists and method
US7262195B2 (en)	2003-09-17	2007-08-28	Bristol-Myers Squibb Company	Compounds useful as motilin agonists and method
AU2004278352B2 (en) *	2003-10-01	2008-10-30	The Procter & Gamble Company	Melanin concentrating hormone antagonists
WO2005063720A1 (ja) *	2003-12-25	2005-07-14	Nippon Shinyaku Co., Ltd.	アミド誘導体及び医薬
WO2005077345A1 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Compounds for the treatment of gastro-esophageal reflux disease
WO2005077368A2 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Treatment of gastro-esophageal reflux disease (gerd)
WO2005077373A2 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Treatment of gastro-esophageal reflux disease (gerd)
US20050277629A1 (en) *	2004-03-18	2005-12-15	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) *	2004-03-18	2007-12-20	Lansbury Peter T	Methods for the treatment of synucleinopathies
SE0401345D0 (sv)	2004-05-25	2004-05-25	Astrazeneca Ab	Therapeutic compounds: Pyridine as scaffold
GB0611907D0 (en)	2006-06-15	2006-07-26	Glaxo Group Ltd	Compounds
JP2009501199A (ja)	2005-07-12	2009-01-15	グラクソグループリミテッド	Ｇｐｒ３８アゴニストとしてのピペラジンヘテロアリール誘導体
MY150098A (en) *	2005-07-26	2013-11-29	Glaxo Group Ltd	Benzylpiperazine derivates and their medical use
SI2041093T1 (sl) *	2006-06-28	2010-07-30	Glaxo Group Ltd	Derivati piperazinila, uporabni pri zdravljenju bolezni, ki jih posreduje receptor gpr38

2007
- 2007-06-26 SI SI200730257T patent/SI2041093T1/sl unknown
- 2007-06-26 CA CA002655540A patent/CA2655540A1/en not_active Abandoned
- 2007-06-26 US US11/768,339 patent/US7700599B2/en not_active Expired - Fee Related
- 2007-06-26 EA EA200970065A patent/EA015820B1/ru not_active IP Right Cessation
- 2007-06-26 JO JO2007261A patent/JO2645B1/en active
- 2007-06-26 DE DE602007006019T patent/DE602007006019D1/de active Active
- 2007-06-26 AT AT07765616T patent/ATE465150T1/de active
- 2007-06-26 PL PL07765616T patent/PL2041093T3/pl unknown
- 2007-06-26 EP EP07765616A patent/EP2041093B1/en active Active
- 2007-06-26 AU AU2007263712A patent/AU2007263712B2/en not_active Ceased
- 2007-06-26 PE PE2007000819A patent/PE20080345A1/es not_active Application Discontinuation
- 2007-06-26 NZ NZ573450A patent/NZ573450A/en not_active IP Right Cessation
- 2007-06-26 MX MX2009000110A patent/MX2009000110A/es active IP Right Grant
- 2007-06-26 HR HR20100284T patent/HRP20100284T1/hr unknown
- 2007-06-26 WO PCT/EP2007/056342 patent/WO2008000729A1/en not_active Ceased
- 2007-06-26 DK DK07765616.3T patent/DK2041093T3/da active
- 2007-06-26 JP JP2009517160A patent/JP5028484B2/ja not_active Expired - Fee Related
- 2007-06-26 ES ES07765616T patent/ES2344484T3/es active Active
- 2007-06-26 KR KR1020087031612A patent/KR20090031688A/ko not_active Ceased
- 2007-06-26 PT PT07765616T patent/PT2041093E/pt unknown
- 2007-06-26 TW TW096122969A patent/TWI391386B/zh not_active IP Right Cessation
- 2007-06-26 BR BRPI0713443-6A patent/BRPI0713443A2/pt not_active IP Right Cessation
- 2007-06-26 AR ARP070102835A patent/AR061656A1/es not_active Application Discontinuation
2008
- 2008-12-11 CR CR10497A patent/CR10497A/es not_active Application Discontinuation
- 2008-12-11 IL IL195900A patent/IL195900A0/en unknown
- 2008-12-24 MY MYPI20085319A patent/MY147677A/en unknown
- 2008-12-30 MA MA31526A patent/MA30539B1/fr unknown
2009
- 2009-01-16 NO NO20090266A patent/NO20090266L/no not_active Application Discontinuation
- 2009-04-02 US US12/417,176 patent/US8853218B2/en not_active Expired - Fee Related
2010
- 2010-06-11 CY CY20101100521T patent/CY1110190T1/el unknown

Also Published As

Publication number	Publication date
MX2009000110A (es)	2009-01-23
MA30539B1 (fr)	2009-06-01
TWI391386B (zh)	2013-04-01
JO2645B1 (en)	2012-06-17
BRPI0713443A2 (pt)	2012-03-06
ES2344484T3 (es)	2010-08-27
PL2041093T3 (pl)	2010-09-30
DK2041093T3 (da)	2010-08-02
US8853218B2 (en)	2014-10-07
AR061656A1 (es)	2008-09-10
AU2007263712A1 (en)	2008-01-03
CA2655540A1 (en)	2008-01-03
JP2009541432A (ja)	2009-11-26
US7700599B2 (en)	2010-04-20
US20080027065A1 (en)	2008-01-31
AU2007263712B2 (en)	2012-08-30
PT2041093E (pt)	2010-06-28
CY1110190T1 (el)	2015-01-14
HK1127608A1 (en)	2009-10-02
HRP20100284T1 (hr)	2010-06-30
US20090192160A1 (en)	2009-07-30
TW200817352A (en)	2008-04-16
EP2041093B1 (en)	2010-04-21
ATE465150T1 (de)	2010-05-15
KR20090031688A (ko)	2009-03-27
EA200970065A1 (ru)	2009-06-30
WO2008000729A1 (en)	2008-01-03
IL195900A0 (en)	2009-09-01
EA015820B1 (ru)	2011-12-30
NZ573450A (en)	2011-11-25
MY147677A (en)	2012-12-31
DE602007006019D1 (de)	2010-06-02
CR10497A (es)	2009-03-20
SI2041093T1 (sl)	2010-07-30
JP5028484B2 (ja)	2012-09-19
PE20080345A1 (es)	2008-05-29
EP2041093A1 (en)	2009-04-01

Publication	Publication Date	Title
NO20090266L (no)	2009-03-17	Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
NO20070487L (no)	2007-03-05	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20061743L (no)	2006-06-21	Kinazolinderivater
NO20081212L (no)	2008-05-06	Xantinderivater som selektive HM74A agonister
NO20083905L (no)	2008-09-12	Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20071246L (no)	2007-05-24	Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20081729L (no)	2008-05-16	Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20082124L (no)	2008-06-20	Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20066081L (no)	2007-02-20	Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20090628L (no)	2009-04-21	Pyridizinon derivativater
NO20073876L (no)	2007-09-10	Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20063599L (no)	2006-10-27	Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20090267L (no)	2009-03-09	Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse
NO20080675L (no)	2008-03-13	P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20092342L (no)	2009-07-02	Azaspiroderivativater
NO20070489L (no)	2007-03-07	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20074258L (no)	2007-11-27	Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20084747L (no)	2008-11-25	Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20084489L (no)	2008-12-19	Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
ATE542795T1 (de)	2012-02-15	Benzylpiperazinderivate als motilin- rezeptorantagonisten
NO20082709L (no)	2008-08-13	Kjemiske forbindelser
NO20081844L (no)	2008-05-29	Terapeutiske forbindelser
NO20082496L (no)	2008-07-24	Pyrazinderivater
GEP20084452B (en)	2008-08-10	Sulfonamide derivatives for the treatment of diseases

Legal Events

Date	Code	Title	Description
2015-01-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application